MBIO MindBio Therapeutics Corp

MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION

• 1 Million Microdoses used to create proprietary microdosing formulation
• MindBio scientists take delivery of GMP grade LSD
• Largest clinical trial repository of biometric, physiological and psychometric data for Microdosing in a big data play for MindBio

Vancouver, British Columbia – May 30, 2023 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the "Company" or "MindBio"), Chief Executive Officer Justin Hanka demonstrates how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with Depression.

All pharmaceutical medicines need to be made to the standard of Good Manufacturing Practices (GMP) which require manufacturers to ensure that their products are traceable, safe, pure and effective for human consumption. MindBio's CEO recently visited its manufacturer in Canada that is fully licensed by the Canadian Government to manufacture GMP grade LSD for the pharmaceutical industry. At the time of the visit the manufacturer had just produced the LSD that would be shipped to MindBio for its Phase 2 Clinical Trials.

https://youtu.be/SJSlpJTvnhA

The GMP grade LSD seen in these jars is used to create a novel sublingual formulation for LSD-microdosing that allows patients to titrate their microdose.  The formulation has long shelf life and is designed to be stored and used at home. 

Co-founder and Chief Executive Officer inspects GMP grade LSD to be used in MindBio's Phase 2 LSD-Microdosing clinical trials.

Through a secure chain of custody, MindBio is pleased to announce the GMP LSD has safely and securely arrived at our labs for processing in preparation for both Phase 2 Clinical Trials.

MindBio's clinical trials have obtained regulatory approvals for at-home use of LSD. At-home use is crucial for testing and modeling the safety and efficacy of psychedelics within the community, as we strive to have these life-saving medicines approved.  MindBio's landmark Phase 1 LSD-Microdosing clinical trial completed in 2022 showed no serious adverse events, and participants in the LSD-Microdosing treatment group reported statistically significant increases in feelings of happiness, social connectivity, wellness, creativity, and energy compared to the placebo group.

Chief Executive Officer and Co-founder of MindBio said "By using microdosing, we are creating a unique treatment model that is globally scalable, accessible, and affordable, aiming to address the existing challenges in mental health care. MindBio is amassing the world's largest repository of biometric, physiological and psychometric data from Microdosing randomised controlled clinical trials in a big data play for the Company. We are leading the world in LSD-Microdosing and look forward to providing the next update to shareholders soon."

We invite you to join us in support of creating a brighter future for mental health.

Receive our latest updates here:  https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn:  https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true

Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/

For further information, please contact:

Justin Hanka, Chief Executive Officer

61 433140886

justin@mindbiotherapeutics.com

About MindBio Therapeutics

MindBio is a biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home LSD-Microdosing human clinical trials.  MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials microdosing Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2 clinical trial in development microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial in development microdosing LSD in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release.  All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.